Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Dabigatran
Drug ID BADD_D00563
Description Dabigatran is the active form of the orally bioavailable prodrug [dabigatran etexilate].
Indications and Usage Not Available
Marketing Status approved; investigational
ATC Code B01AE07
DrugBank ID DB14726
KEGG ID D09707
MeSH ID D000069604
PubChem ID 216210
TTD Drug ID D0M7JT
NDC Product Code 51869-0030
UNII I0VM4M70GC
Synonyms Dabigatran | N-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)-N-2-pyridinyl-beta-alanine | BIBR 1048 | Pradaxa | Dabigatran Etexilate | Etexilate, Dabigatran | Dabigatran Etexilate Mesylate | Etexilate Mesylate, Dabigatran | Mesylate, Dabigatran Etexilate
Chemical Information
Molecular Formula C25H25N7O3
CAS Registry Number 211914-51-1
SMILES CN1C2=C(C=C(C=C2)C(=O)N(CCC(=O)O)C3=CC=CC=N3)N=C1CNC4=CC=C(C=C4)C(=N)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Venous thrombosis24.01.01.0080.001835%Not Available
Vitreous haemorrhage24.07.05.005; 06.10.03.0010.001223%
Volvulus07.13.01.0120.001223%Not Available
Pneumoperitoneum07.07.01.0080.000612%Not Available
Hydrothorax22.05.02.0040.000245%Not Available
Intestinal polyp16.05.01.002; 07.20.01.0090.000489%Not Available
Intracardiac thrombus02.11.01.017; 24.01.05.0030.009003%Not Available
Coronary artery dissection24.02.02.001; 02.02.01.004; 12.02.01.0350.000245%Not Available
Ischaemic cardiomyopathy24.04.04.019; 02.04.01.0040.000489%Not Available
Brain oedema12.01.10.010; 17.07.02.0030.003915%
Carotid artery occlusion24.04.06.008; 17.08.01.0120.002447%Not Available
Spinal cord haemorrhage24.07.04.010; 17.08.01.030; 12.01.13.0030.000612%Not Available
Brain death08.04.01.004; 17.02.03.0030.001101%Not Available
Oesophagitis ulcerative07.04.05.0030.000612%Not Available
Sudden cardiac death02.03.04.016; 08.04.01.0080.001101%Not Available
Anal haemorrhage24.07.02.029; 07.12.03.0040.000612%
Quadriparesis17.01.04.0120.000245%Not Available
Urethral haemorrhage24.07.03.006; 20.07.01.0030.000734%Not Available
Tumour haemorrhage24.07.01.028; 16.32.03.0080.000734%
Pituitary haemorrhage24.07.04.009; 17.08.01.019; 05.03.04.0050.000245%Not Available
Bradyarrhythmia02.03.02.0150.000245%Not Available
Shock haemorrhagic24.06.02.014; 14.05.05.0030.017738%Not Available
Left ventricular hypertrophy02.04.02.0140.000367%Not Available
Abnormal clotting factor01.01.02.0050.000538%Not Available
Dry gangrene24.04.03.018; 23.06.06.0030.000367%Not Available
Cardiac death08.04.01.007; 02.03.04.0150.000367%Not Available
Lung cancer metastatic16.19.02.003; 22.08.01.0040.000734%Not Available
Urogenital haemorrhage20.08.01.006; 24.07.01.044; 21.10.05.0080.001028%Not Available
Spinal epidural haematoma17.08.01.038; 12.01.13.006; 24.07.04.0200.000245%Not Available
Scleral haemorrhage06.07.01.002; 24.07.05.0090.000245%Not Available
The 12th Page    First    Pre   12 13 14 15 16    Next   Last    Total 22 Pages